Biblio

Export 125 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Biomarkers  [Clear All Filters]
2016
L. Xu, Wu, X., Li, R., Chen, K., Long, Z., Zhang, J., Guo, X., and Yao, L., Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers., J Alzheimers Dis, vol. 51, no. 4, pp. 1045-56, 2016.
J. Wang, Tan, L., and Yu, J. - T., Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives., J Alzheimers Dis, vol. 50, no. 4, pp. 927-45, 2016.
E. Morenas-Rodriguez, Cervera-Carles, L., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Dols-Icardo, O., Ribosa-Nogué, R., Muñoz-Llahuna, L., Sala, I., M Sánchez-Saudinós, B., Blesa, R., Clarimón, J., Fortea, J., and Lleo, A., Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias., J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., Spatial Navigation in Preclinical Alzheimer's Disease., J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
N. Pierrot, Lhommel, R., Quenon, L., Hanseeuw, B., Dricot, L., Sindic, C., Maloteaux, J. - M., Octavea, J. - N., and Ivanoiu, A., Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers., J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
A. L. Jefferson, Gifford, K. A., Mae Y Acosta, L., Bell, S. P., Donahue, M. J., L Davis, T., Gottlieb, J. A., Gupta, D. K., Hohman, T. J., Lane, E. M., Libon, D. J., Mendes, L. A., Niswender, K., Pechman, K. R., Rane, S., Ruberg, F. L., Su, Y. Ru, Zetterberg, H., and Liu, D., The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview., J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
S. E. Leh, Kälin, A. M., Schroeder, C., Park, M. Tae M., M Chakravarty, M., Freund, P., Gietl, A. F., Riese, F., Kollias, S., Hock, C., and Michels, L., Volumetric and shape analysis of the thalamus and striatum in amnestic mild cognitive impairment., J Alzheimers Dis, vol. 49, no. 1, pp. 237-49, 2016.
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
2014
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria., Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
M. Mapstone, Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Federoff, H. J., Plasma phospholipids identify antecedent memory impairment in older adults., Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
2011
T. E. Golde, Schneider, L. S., and Koo, E. H., Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift., Neuron, vol. 69, no. 2, pp. 203-13, 2011.
G. M. McKhann, Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., and Phelps, C. H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement, vol. 7, no. 3, pp. 263-9, 2011.
M. S. Albert, DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., and Phelps, C. H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
C. R. Jack, Vemuri, P., Wiste, H. J., Weigand, S. D., Aisen, P. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Petersen, R. C., Weiner, M. W., and Knopman, D. S., Evidence for ordering of Alzheimer disease biomarkers., Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
J. M. Castellano, Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M., Human apoE isoforms differentially regulate brain amyloid-β peptide clearance., Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
P. S. Aisen, Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., Hendrix, S. B., Grundman, M., Schneider, L. S., Schindler, R. J., Salmon, E., Potter, W. Z., Thomas, R. G., Salmon, D., Donohue, M., Bednar, M. M., Touchon, J., and Vellas, B., Report of the task force on designing clinical trials in early (predementia) AD., Neurology, vol. 76, no. 3, pp. 280-6, 2011.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.

Pages